Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Roberts

Showing results (141-150 of 198) with videos related to

Pageof 20
Sort By:
Blood|June 26, 2016
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemiaSeong Lin Khaw, Santi Suryani, Kathryn Evans, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
ASM Case Reports|November 17, 2025
A case of enterovirus D68-associated acute flaccid myelitis in an immunocompromised adult, AustraliaNathaniel Lizak, Grace Butel-Simoes, Eike Steinig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive ChemotherapyChong Chyn Chua, Andrew W Roberts, John Reynolds, et al.
Cancer Cell|April 26, 2024
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancersSarah T Diepstraten, Yin Yuan, John E La Marca, et al.
The New England Journal of Medicine|March 29, 2018
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaConstantine S Tam, Mary Ann Anderson, Christiane Pott, et al.
Blood Advances|December 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphomaSasanka M Handunnetti, Amit Khot, Piers Blombery, et al.
Cell Death and Differentiation|January 29, 2020
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cellsCharis E Teh, Jia-Nan Gong, David Segal, et al.
Blood|April 24, 2009
Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant functionSimone M Schoenwaelder, Yuping Yuan, Emma C Josefsson, et al.
Blood|April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W Roberts, Shuo Ma, Thomas J Kipps, et al.
Pageof 20

Showing results (141-150 of 198) with videos related to

Sort By:
Pageof 20
Blood|June 26, 2016
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemiaSeong Lin Khaw, Santi Suryani, Kathryn Evans, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
ASM Case Reports|November 17, 2025
A case of enterovirus D68-associated acute flaccid myelitis in an immunocompromised adult, AustraliaNathaniel Lizak, Grace Butel-Simoes, Eike Steinig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive ChemotherapyChong Chyn Chua, Andrew W Roberts, John Reynolds, et al.
Cancer Cell|April 26, 2024
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancersSarah T Diepstraten, Yin Yuan, John E La Marca, et al.
The New England Journal of Medicine|March 29, 2018
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaConstantine S Tam, Mary Ann Anderson, Christiane Pott, et al.
Blood Advances|December 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphomaSasanka M Handunnetti, Amit Khot, Piers Blombery, et al.
Cell Death and Differentiation|January 29, 2020
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cellsCharis E Teh, Jia-Nan Gong, David Segal, et al.
Blood|April 24, 2009
Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant functionSimone M Schoenwaelder, Yuping Yuan, Emma C Josefsson, et al.
Blood|April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W Roberts, Shuo Ma, Thomas J Kipps, et al.
Pageof 20